GLP-1 medications, already widely used to treat obesity and type 2 diabetes, may offer an additional benefit: helping the heart recover from a heart attack by restoring blood flow through tiny blocked vessels. A new study led by researchers at the University of Bristol and University College London (UCL), published in Nature Communications, points to a specific biological mechanism that could explain why these drugs appear to protect the heart.
The “No-Reflow” Problem
When a patient suffers a heart attack, emergency treatment typically focuses on reopening the main blocked artery. But in nearly half of all heart attack patients, that intervention isn’t enough. Tiny blood vessels within the heart muscle remain narrowed, preventing blood from reaching certain areas of heart tissue. Clinicians call this “no-reflow.”
The condition is not minor. It raises the risk of death or hospital admission for heart failure within a year of a heart attack. Until now, treatment options to address it directly have been limited.
What the Research Found
The Bristol and UCL team had previously identified small contractile cells called pericytes as a key factor. During the early stages of ischemia, when the heart muscle is starved of oxygen-rich blood, pericytes tighten around coronary capillaries, constricting them. The new study examined whether GLP-1 drugs could reverse that process.
Experiments using animal models showed that they can. The drugs activate potassium channels in coronary pericytes, causing those cells to relax. When pericytes relax, the constricted capillaries widen, and blood flow resumes to tissue that would otherwise remain starved of oxygen.
Dr. Svetlana Mastitskaya, Senior Lecturer in Cardiovascular Regenerative Medicine at Bristol Medical School and the study’s lead author, described the findings as unexpected: “Our latest findings are surprising in that we have found GLP-1 drugs may prevent this problem.”
Why This Matters Beyond Weight Loss
GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, have already demonstrated cardiovascular benefits in earlier research, with those benefits appearing regardless of weight loss or pre-existing health conditions. The new findings point toward a distinct, targeted mechanism that could make these drugs useful well beyond their current approved indications.
Professor David Attwell, Jodrell Professor of Physiology at UCL and co-lead of the study, pointed to the clinical opportunity: “With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of ‘no-reflow’ in heart attack patients.”
Repurposing an existing, approved class of drugs carries practical advantages. The safety profiles are already established, and the regulatory pathway for new indications is generally shorter than for entirely new compounds.
What Comes Next
The current findings are based on animal models, and human trials would be required before GLP-1 drugs could be formally recommended for post-heart attack care targeting no-reflow. The study, published in Nature Communications, was supported in part by the British Heart Foundation, which funds Dr. Mastitskaya’s research.
The work adds a concrete biological explanation to a pattern that cardiologists had already observed: patients taking GLP-1 medications tend to fare better after cardiac events. Now there is a clearer picture of why.
Photo by Vitaly Gariev on Unsplash
This article is a curated summary based on third-party sources. Source: Read the original article
